[1] 吴凌云,常春康. 骨髓增生异常综合征的诊治最新进展. 诊断学理论与实践,2019,18(06):623-629.
[2] 宋晓颖. 红细胞参数及血清学指标在骨髓增生异常综合征中的临床意义. 华北理工大学,2020.
[3] 宋怡然. 红细胞分布宽度与肝硬化病程及Child-Pugh分级的相关性研究. 昆明医科大学,2018.
[4] 梁会萍,王颖,李丹,等. 外周血细胞参数对早期识别骨髓增生异常综合征患者诊断价值的研究. 中国实验血液学杂志,2021,29(04):1231-1235.
[5] 李红卫. 白细胞计数 血小板计数 红细胞比容 红细胞与骨髓增生异常综合征患者病情程度的关联性及临床意义. 中国药物与临床,2021,21(15):2736-2738.
[6] 梁扩寰,李绍白. 肝脏病学. 北京:人民卫生出版社,2003.
[7] 费成明,常春康. 骨髓增生异常综合征造血微环境若干问题研究进展. 中国实验血液学杂志,2012,20(05):1246-1250.
[8] Ratnasari N, Nurdjanah S, Sadewa AH, et al. Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population. PLoS One,2017,12(8):e183503.
[9] Kim HO, Kim SK, Son BH, et al. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach. Hepatobiliary Pancreat Dis Int,2009,8(6):591-596.
[10] Ribeiro OD, Canedo NH, Pannain VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features. Clinics (Sao Paulo),2016,71(11):639-643.
[11] 姚运海,罗艳,朱京乐,等. 肝硬化合并门静脉血栓患者外周血血管内皮生长因子的检测及意义. 临床肝胆病杂志,2020,36(09):1966-1969.
[12] Faccia M, Ainora ME, Ponziani FR, et al. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J Gastroenterol,2019,25(31):4437-4451.
[13] 李玲,陈世耀. 从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素. 实用肝脏病杂志,2015,18(03):325-328.
[14] Noronha FC, Marinho RT, Cortez-Pinto H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. Liver Int,2019,39(8):1459-1467.
[15] 王芸,耿嘉蔚,王罡,等. 多层螺旋CT对慢性白血病并发区域性门脉高压的诊疗分析. 昆明医科大学学报,2012,33(07):132-133.
[16] 张国,王文娟. 《肝硬化门静脉血栓管理专家共识》解读. 中国临床新医学,2021,14(08):740-744. |
